PLAY PODCASTS
212: Resiliency Radio with Dr. Jill: Psychedelic Therapy and the New Frontier of Mental Health with Dr. Will Van Derveer
Season 5 · Episode 212

212: Resiliency Radio with Dr. Jill: Psychedelic Therapy and the New Frontier of Mental Health with Dr. Will Van Derveer

Resiliency Radio with Dr. Jill Carnahan, MD

August 15, 202455m 22s

Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

Dr. Will Van Derveer, joins Dr. Jill Carnahan to discuss the promising advancements and therapeutic benefits of psychedelic substances in treating mental health conditions like **PTSD**. Dr. Van Derveer is a renowned expert in integrative psychiatry and brings invaluable insights into how these unconventional therapies are reshaping the future of mental health care.

Key Points ✅ Could psychedelics may become legal and appropriate treatment for depression and PTSD this year? ✅ What are the different potential indications of NMDA, psilocybin (magic mushrooms) or ketamine therapy in the treatment of psychiatric disorders and PTSD ✅ Why is it important to have trained medical staff and therapists for these types of therapies and their success in treating patients with depression, anxiety or PTSD

Will Van Derveer, MD Will Van Derveer, MD is co-founder of Integrative Psychiatry Institute, which offers comprehensive training for mental health professionals in psychedelic-assisted psychotherapy and other continuing education programs.

He is medical director of Integrative Psychiatry Center of Boulder, CO, providing integrative psychiatry for a broad range of conditions and ketamine-assisted psychotherapy for treatment-resistant depression and PTSD. In addition to his clinical practice and teaching, he has been involved with several studies sponsored by MAPS, investigating MDMA-assisted psychotherapy for chronic, treatment-resistant PTSD, a breakthrough treatment which could be approved in late 2024 by FDA.